Sarah Elizabeth Wheeler

Sarah Elizabeth Wheeler

Auto-generated profile, based on publicly available information

Sarah Elizabeth Wheeler

Department of Pathology, University of Pittsburgh School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
ETElitza S Theel
Elitza S Theel
PSPatricia Slev
Patricia Slev
SWSarah Wheeler
Sarah Wheeler
MCMarc Roger Couturier
Marc Roger Couturier
SWSusan J Wong
Susan J Wong
KKKamran Kadkhoda
Kamran Kadkhoda
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen, and the acceptable specimen types.

1 February 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
CBColin H. Beckwitt
Colin H. Beckwitt
Amanda M ClarkAmanda M Clark
Amanda M Clark
SWSarah Wheeler
Sarah Wheeler
DTD. Lansing Taylor
D. Lansing Taylor
DSDonna B. Stolz
Donna B. Stolz
Alan WellsAlan Wells
Alan Wells

1 May 2013 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
Alan WellsAlan Wells
Alan Wells
Jelena GrahovacJelena Grahovac
Jelena Grahovac
SWSarah Wheeler
Sarah Wheeler
Bo MaBo Ma
Bo Ma
DLDouglas Lauffenburger
Douglas Lauffenburger
Advances in diagnosis and treatment have rendered most solid tumors largely curable if they are diagnosed and treated before dissemination. However, once they spread beyond the initial primary location, these cancers are usually highly morbid, if not fatal. Thus, current efforts focus on both limiting initial dissemination and preventing secondary spread. There are two modes of tumor dissemination - invasion and metastasis - each leading to unique therapeutic challenges and likely to be driven by distinct mechanisms. However, these two forms of dissemination utilize some common strategies to accomplish movement from the primary tumor, establishment in an ectopic site, and survival therein. The adaptive behaviors of motile cancer cells provide an opening for therapeutic approaches if we understand the molecular, cellular, and tissue biology that underlie them. Herein, we review the signaling cascades and organ reactions that lead to dissemination, as these are non-genetic in nature, focusing on cell migration as the key to tumor progression. In this context, the cellular phenotype will also be discussed because the modes of migration are dictated by quantitative and physical aspects of the cell motility machinery.

3 September 2021 in Microbiology Spectrum
Verified
Journal Article
Open access
SWSarah E Wheeler
Sarah E Wheeler
GSGalina V Shurin
Galina V Shurin
MYMary Yost
Mary Yost
AAAdam Anderson
Adam Anderson
LPLisa Pinto
Lisa Pinto
Michael ShurinMichael Shurin
Michael Shurin
Now that authorized vaccines for COVID-19 have been widely used, it is important to understand how they induce antivirus antibodies, which antigens are targeted, how long antibodies circulate, and how personal health conditions and age may affect this humoral immunity. Here, we report induction and time course of multiple anti-SARS-CoV-2 antibody responses in healthy individuals immunized with Pfizer and Moderna mRNA vaccines.

1 November 2020 in Journal of General Virology
Verified
Journal Article
Open access
WKWilliam B. Klimstra
William B. Klimstra
NTNatasha Tilston-Lunel
Natasha Tilston-Lunel
SNSham Nambulli
Sham Nambulli
JBJames Boslett
James Boslett
CMCynthia M. McMillen
Cynthia M. McMillen
WWWewee Wewewe
Wewee Wewewe
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged at the end of 2019 and by mid-June 2020 the virus had spread to at least 215 countries, caused more than 8 000 000 confirmed infections and over 450 000 deaths, and overwhelmed healthcare systems worldwide. Like severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 and caused a similar disease, SARS-CoV-2 is a betacoronavirus. Both viruses use human angiotensin-converting enzyme 2 (hACE2) as a receptor to enter cells. However, the SARS-CoV-2 spike (S) glycoprotein has a novel insertion that generates a putative furin cleavage signal and this has been postulated to expand the host range. Two low-passage (P) strains of SARS-CoV-2 (Wash1 : P4 and Munich : P1) were cultured twice in Vero E6 cells and characterized virologically. Sanger and MinION sequencing demonstrated significant deletions in the furin cleavage signal of Wash1 : P6 and minor variants in the Munich : P3 strain. Cleavage of the S glycoprotein in SARS-CoV-2-infected Vero E6 cell lysates was inefficient even when an intact furin cleavage signal was present. Indirect immunofluorescence demonstrated that the S glycoprotein reached the cell surface. Since the S protein is a major antigenic target for the development of neutralizing antibodies, we investigated the development of neutralizing antibody titres in serial serum samples obtained from COVID-19 human patients. These were comparable regardless of the presence of an intact or deleted furin cleavage signal. These studies illustrate the need to characterize virus stocks meticulously prior to performing either in vitro or in vivo pathogenesis studies.

1 June 2013 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SWSarah Elizabeth Wheeler
Sarah Elizabeth Wheeler
HSHuifang Shi
Huifang Shi
FLFangchen Lin
Fangchen Lin
SDSumana Dasari
Sumana Dasari
JBJoseph Bednash Bs
Joseph Bednash Bs
STSufi Mary Thomas
Sufi Mary Thomas